LanZhou Foci Pharmaceutical Co.,Ltd. (002644.SZ)
CNY 8.12
(0.25%)
CNY 8.12
(0.25%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 759.67 Million CNY | -10.9% |
| 2022 | 852.59 Million CNY | 17.67% |
| 2021 | 724.59 Million CNY | -9.44% |
| 2020 | 800.08 Million CNY | -10.48% |
| 2019 | 893.77 Million CNY | -17.52% |
| 2018 | 1.08 Billion CNY | 9.38% |
| 2017 | 990.67 Million CNY | 32.78% |
| 2016 | 746.13 Million CNY | 479.45% |
| 2015 | 128.76 Million CNY | -58.65% |
| 2014 | 311.39 Million CNY | 55.93% |
| 2013 | 199.7 Million CNY | 35.5% |
| 2012 | 147.38 Million CNY | -18.64% |
| 2011 | 181.14 Million CNY | 39.67% |
| 2010 | 129.69 Million CNY | -23.3% |
| 2009 | 169.09 Million CNY | -7.96% |
| 2008 | 183.7 Million CNY | 11.53% |
| 2007 | 164.72 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 740.43 Million CNY | -2.53% |
| 2024 Q3 | 677.62 Million CNY | 55.0% |
| 2024 Q2 | 437.16 Million CNY | -40.96% |
| 2023 Q3 | 794.1 Million CNY | -4.54% |
| 2023 FY | 759.67 Million CNY | -10.9% |
| 2023 Q2 | 831.87 Million CNY | -12.02% |
| 2023 Q4 | 759.67 Million CNY | -4.34% |
| 2023 Q1 | 945.48 Million CNY | 10.9% |
| 2022 Q2 | 777.59 Million CNY | -4.17% |
| 2022 Q4 | 852.59 Million CNY | 20.92% |
| 2022 FY | 852.59 Million CNY | 17.67% |
| 2022 Q1 | 811.43 Million CNY | 11.99% |
| 2022 Q3 | 705.11 Million CNY | -9.32% |
| 2021 FY | 724.59 Million CNY | -9.44% |
| 2021 Q1 | 806.09 Million CNY | 0.75% |
| 2021 Q2 | 900.04 Million CNY | 11.65% |
| 2021 Q3 | 873.91 Million CNY | -2.9% |
| 2021 Q4 | 724.59 Million CNY | -17.09% |
| 2020 Q2 | 781.78 Million CNY | -6.69% |
| 2020 Q1 | 837.82 Million CNY | -6.26% |
| 2020 Q4 | 800.08 Million CNY | 12.9% |
| 2020 Q3 | 708.66 Million CNY | -9.35% |
| 2020 FY | 800.08 Million CNY | -10.48% |
| 2019 Q4 | 893.77 Million CNY | -3.88% |
| 2019 FY | 893.77 Million CNY | -17.52% |
| 2019 Q2 | 946.23 Million CNY | -5.86% |
| 2019 Q1 | 1 Billion CNY | -7.24% |
| 2019 Q3 | 929.81 Million CNY | -1.73% |
| 2018 Q3 | 956.47 Million CNY | 2.01% |
| 2018 Q1 | 937.86 Million CNY | -5.33% |
| 2018 FY | 1.08 Billion CNY | 9.38% |
| 2018 Q4 | 1.08 Billion CNY | 13.29% |
| 2018 Q2 | 937.62 Million CNY | -0.03% |
| 2017 Q3 | 861.6 Million CNY | 4.07% |
| 2017 Q4 | 990.67 Million CNY | 14.98% |
| 2017 FY | 990.67 Million CNY | 32.78% |
| 2017 Q1 | 767.52 Million CNY | 2.87% |
| 2017 Q2 | 827.89 Million CNY | 7.87% |
| 2016 Q2 | 434.91 Million CNY | 10.08% |
| 2016 FY | 746.13 Million CNY | 479.45% |
| 2016 Q4 | 746.13 Million CNY | 59.64% |
| 2016 Q3 | 467.37 Million CNY | 7.46% |
| 2016 Q1 | 395.08 Million CNY | 206.83% |
| 2015 Q4 | 128.76 Million CNY | -53.71% |
| 2015 Q1 | 292.12 Million CNY | -6.19% |
| 2015 Q2 | 314.92 Million CNY | 7.8% |
| 2015 Q3 | 278.19 Million CNY | -11.66% |
| 2015 FY | 128.76 Million CNY | -58.65% |
| 2014 Q4 | 311.39 Million CNY | 10.32% |
| 2014 FY | 311.39 Million CNY | 55.93% |
| 2014 Q3 | 282.25 Million CNY | -4.05% |
| 2014 Q2 | 294.16 Million CNY | -15.4% |
| 2014 Q1 | 347.7 Million CNY | 74.11% |
| 2013 Q3 | 192.12 Million CNY | 49.96% |
| 2013 FY | 199.7 Million CNY | 35.5% |
| 2013 Q1 | 126.9 Million CNY | -13.89% |
| 2013 Q2 | 128.11 Million CNY | 0.95% |
| 2013 Q4 | 199.7 Million CNY | 3.95% |
| 2012 Q3 | 118.77 Million CNY | -3.68% |
| 2012 Q2 | 123.3 Million CNY | -5.34% |
| 2012 Q1 | 130.25 Million CNY | -28.09% |
| 2012 FY | 147.38 Million CNY | -18.64% |
| 2012 Q4 | 147.38 Million CNY | 24.09% |
| 2011 Q4 | 181.14 Million CNY | 19.6% |
| 2011 Q3 | 151.45 Million CNY | -4.52% |
| 2011 FY | 181.14 Million CNY | 39.67% |
| 2011 Q2 | 158.62 Million CNY | 0.0% |
| 2010 FY | 129.69 Million CNY | -23.3% |
| 2010 Q4 | 129.69 Million CNY | 0.0% |
| 2009 FY | 169.09 Million CNY | -7.96% |
| 2008 FY | 183.7 Million CNY | 11.53% |
| 2007 FY | 164.72 Million CNY | 0.0% |